BioCryst signs two more non-US partnerships for peramivir
This article was originally published in Scrip
Executive Summary
The US company BioCryst Pharmaceuticals has signed agreements with two additional partners for its investigational antiviral treatment peramivir, for influenza stockpiling opportunities in territories outside of the US.